Royalty Pharma (RPRX) Total Debt (2019 - 2026)

Royalty Pharma has disclosed Total Debt across 8 years of filings, most recently posting $9.3 billion for Q2 2026.

• In Q2 2026, Total Debt rose 3.78% year-over-year to $9.3 billion; the TTM figure through Jun 2026 stood at $9.3 billion (up 3.78% YoY), while the FY2025 annual figure was $9.3 billion, up 8.37% from the prior year.
• Total Debt came in at $9.3 billion for Q2 2026 at Royalty Pharma, roughly flat from $9.3 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $9.3 billion in Q2 2026 to a low of $6.1 billion in Q3 2023.
• Average Total Debt over 5 years is $8.1 billion, with a median of $8.2 billion recorded in 2022.
• Year-over-year, Total Debt retreated 25.35% in 2023 and soared 40.34% in 2025.
• Over 5 years, Total Debt stood at $8.2 billion in 2022, then declined by 25.26% to $6.1 billion in 2023, then jumped by 40.34% to $8.6 billion in 2024, then rose by 8.37% to $9.3 billion in 2025, then rose by 0.12% to $9.3 billion in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $9.3 billion in Q2 2026, $9.3 billion in Q1 2026, and $9.3 billion in Q4 2025.